NCT02413099View on ClinicalTrials.gov

The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

January 3, 2013

Conditions
Erectile Dysfunction
Interventions
DRUG

KBMSI-2

The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.

Trial Locations (1)

602-739

Department of Urology, Pusan National University Hospital, Busan

All Listed Sponsors
lead

Hyun Jun Park

OTHER

NCT02413099 - The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction | Biotech Hunter | Biotech Hunter